"AnchorDx plans to use the new funds to accelerate the registration and commercialization of its NGS-based products for single-cancer, multi-cancer, and pan-cancer screening and early detection. The company also plans to deploy its technology to other major disease areas...."
AnchorDx Completes USD 40 Million Series C Financing to Advance Cancer Screening and Early Detection
022221 AnchorDx Completes USD 40 Million
Download • 46KB